Legal advisor to the management of Julius Clinical on sale to Ampersand Capital Partners

Acted as legal advisor to the management of Julius Clinical Research in connection with the sale to Ampersand Capital Partners.

Julius Clinical is a contract research organization active in clinical research. The investment by Ampersand Capital Partners was intended to support further growth and international expansion, including in Europe and North America. Dealmaker lists the transaction as “Ampersand Capital Partners acquires Julius Clinical”, with a EUR 25–50 million transaction value category and a transaction date of 23 November 2023.

The legal work focused on the management position in the transaction, sale documentation, management participation and arrangements with the new investor. In private equity transactions involving management, the sale, reinvestment, governance and future management position need to be carefully aligned.

Need legal advice on a private equity transaction or management participation?

For questions about management participation, reinvestment, shareholder documentation or private equity transactions, please contact dirk.dewaard@viottalaw.com.

Deal highlights

Transaction type – Sale / private equity transaction / management participation

Client – Management of Julius Clinical Research

Buyer – Ampersand Capital Partners

Sector – Life sciences / clinical research / CRO

Role – Legal advisor to management

Legal work – Transaction documentation, management position, reinvestment, governance and private equity arrangements

Links
Dealmaker — Ampersand Capital Partners acquires Julius Clinical
Julius Clinical press release
PR Newswire

Related expertise

Private equity
Corporate / M&A
Shareholders agreement
Investment agreement
Commercial contracts

Involved lawyers.

If you need a legal opinion under Dutch law, please do not hesitate to contact us via
info@viottalaw.com or +31 20 248 06 00.

By VIOTTA.

Recent cases.

By VIOTTA.

More articles.

16 / 10 2026

Lessons from Cross-Border Transactions: Dutch Deal Execution in Practice

Practical observations from cross-border transactions involving Dutch companies, focusing on transaction management, drafting, due diligence, closing mechanics and Dutch implementation.

READ ARTICLE
16 / 10 2026

Preparing a Dutch Company for Investment or Sale

A practical Dutch deal-readiness guide covering ownership, governance, contracts, IP, management incentives, corporate approvals and data-room preparation before an investment or sale.

READ ARTICLE
15 / 10 2026

VC Term Sheets in Dutch Financing Rounds: What Is Binding and What Is Not?

A practical insight for international investors and counsel on Dutch VC term sheets: which commercial terms remain non-binding, which process provisions should bind immediately and how the term sheet moves into Dutch BV financing documentation.

READ ARTICLE
08 / 10 2026

Can a Dutch NV Remain TopCo for a Nasdaq Listing? The InoBat Structure

The proposed InoBat transaction shows how a Dutch N.V. can serve as TopCo in a Nasdaq structure involving preference shares, warrants, employee options and PIPE financing.

READ ARTICLE
08 / 10 2026

Digital Shareholder Meetings in Dutch Companies from 2027

From 1 January 2027, Dutch companies can use fully digital shareholder meetings if the articles and meeting process meet the statutory requirements. The change is relevant for international shareholder governance and transaction approvals.

READ ARTICLE
08 / 10 2026

Share Options for Dutch Employees Under a Foreign Parent Company Plan

Foreign parent companies can grant options to employees of a Dutch subsidiary. This insight explains the Dutch implementation layer: local documentation, grant administration, employee mobility and the treatment of Dutch participants in a group exit.

READ ARTICLE